These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH. Chan CK; Mein CE; Glassman AR; Beaulieu WT; Calhoun CT; Jaffe GJ; Jampol LM; MacCumber MW; Maguire MG; Maturi RK; Salehi-Had H; Rofagha S; Sun JK; Martin DF; Ophthalmology; 2021 Nov; 128(11):1592-1603. PubMed ID: 33989683 [TBL] [Abstract][Full Text] [Related]
5. Anatomical and functional outcomes of pneumatic vitreolysis for treatment of vitreomacular traction with and without macular holes. Baumann C; Sabatino F; Zheng Y; Johannigmann-Malek N; Maier M; Kaye SB; Patton N Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2209-2215. PubMed ID: 35122133 [TBL] [Abstract][Full Text] [Related]
6. INTRAVITREAL OCRIPLASMIN IN CLINICAL PRACTICE: Predictors of Success, Visual Outcomes, and Complications. Feng HL; Roth DB; Hasan A; Fine HF; Wheatley HM; Prenner JL; Shah SP; Modi KK; Feuer WJ Retina; 2018 Jan; 38(1):128-136. PubMed ID: 28106706 [TBL] [Abstract][Full Text] [Related]
7. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy]. Maier M; Abraham S; Frank C; Lohmann CP; Feucht N Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007 [TBL] [Abstract][Full Text] [Related]
8. Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis. Thomas AS; Folgar FA; Jaffe GJ; Toth CA; Mahmoud TH Ophthalmol Retina; 2019 Jan; 3(1):42-52. PubMed ID: 30929816 [TBL] [Abstract][Full Text] [Related]
9. Pneumatic Vitreolysis for the Treatment of Vitreomacular Traction Syndrome. Özdemir HB; Özdek Ş; Hasanreisoğlu M Turk J Ophthalmol; 2019 Sep; 49(4):201-208. PubMed ID: 31486607 [TBL] [Abstract][Full Text] [Related]
10. Enzymatic Vitreolysis for Vitreomacular Traction in Diabetic Retinopathy. Rizzo S; Bacherini D Dev Ophthalmol; 2017; 60():160-164. PubMed ID: 28427074 [TBL] [Abstract][Full Text] [Related]
11. Short-term changes in posterior vitreous cortex following intravitreal ocriplasmin for symptomatic vitreomacular traction syndrome: a prospective study. Cacciamani A; Gattegna R; Pileri M; Di Nicola M; Bardanzellu S; Facciolo G; Cosimi P; Govetto A; Scarinci F Int Ophthalmol; 2020 Jan; 40(1):185-193. PubMed ID: 31565760 [TBL] [Abstract][Full Text] [Related]
12. [Initial Clinical Experiences Using Ocriplasmin for the Treatment of Vitreomacular Traction with or without a Macular Hole]. Lenk J; Matthé E; Ventzke S; Pillunat LE; Sandner D Klin Monbl Augenheilkd; 2018 Jan; 235(1):73-80. PubMed ID: 28282697 [TBL] [Abstract][Full Text] [Related]
13. PNEUMATIC VITREOLYSIS FOR RELIEF OF VITREOMACULAR TRACTION. Chan CK; Crosson JN; Mein CE; Daher N Retina; 2017 Oct; 37(10):1820-1831. PubMed ID: 28099316 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes. Sharma P; Juhn A; Houston SK; Fineman M; Chiang A; Ho A; Regillo C Am J Ophthalmol; 2015 May; 159(5):861-7.e2. PubMed ID: 25660387 [TBL] [Abstract][Full Text] [Related]
15. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study. Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657 [TBL] [Abstract][Full Text] [Related]
16. Pneumatic Vitreolysis With Intravitreal Air for Focal Vitreomacular Traction. Seamone ME; Rubin U; Grewal PS; Greve M J Vitreoretin Dis; 2021; 5(4):348-353. PubMed ID: 37007599 [TBL] [Abstract][Full Text] [Related]
17. Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics. Bertelmann T; Berndzen L; Raber T; Pfeiffer S; Leha A; Paul C; Feltgen N; Bemme S Sci Rep; 2021 Dec; 11(1):24096. PubMed ID: 34916576 [TBL] [Abstract][Full Text] [Related]
18. Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications. Chatziralli I; Theodossiadis G; Xanthopoulou P; Miligkos M; Sivaprasad S; Theodossiadis P Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1247-56. PubMed ID: 27137631 [TBL] [Abstract][Full Text] [Related]
19. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole. Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122 [TBL] [Abstract][Full Text] [Related]
20. INTRAVITREAL SULFUR HEXAFLUORIDE INJECTION FOR THE TREATMENT OF VITREOMACULAR TRACTION SYNDROME. Day S; Martinez JA; Nixon PA; Levitan M; Dooner JW; Wong RW; Harper CA Retina; 2016 Apr; 36(4):733-7. PubMed ID: 26383712 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]